Yükleniyor... / Loading...
This study examines the use of immune T cells whose PD-1 gene has been switched off (knocked out) through gene editing, in patients with advanced esophageal cancer. It was open to patients with recurrent or metastatic esophageal cancer that had progressed after standard treatments. It was conducted as a study with no assigned phase and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Histologically confirmed recurrent or metastatic esophageal cancer * Measurable disease * Progressed after standard treatments * ECOG performance status of 0-2 * Expected life span: \>= 3 months * Toxicities from prior treatment has resolved or ≤ grade 1 * Major organs function normally * Women at pregnant ages should be under contraception * Willing and able to provide informed consent Exclusion Criteria: * Other malignancy within 5 years prior to entry into the study, expect for treated non-melanoma skin cancer and cervical carcinoma in situ * Poor vasculature * Disease to the central nervous system * Blood-borne infectious disease, e.g. hepatitis B * History of mandatory custody because of psychosis or other psychological disease inappropriate for treatment deemed by treating physician * With other immune diseases, or chronic use of immunosuppressants or steroids * Pregnancy (women of childbearing potential:Refusal or inability to use effective means of contraception) * Breastfeeding * Decision of unsuitableness by principal investigator or physician-in-charge